A new perspective on the proper timing of radiotherapy during CDK4/6 inhibitor therapy in patients with “bone-only” metastatic breast cancer
The vast majority of hormone positive and HER2 negative advanced breast cancers can be controlled well by endocrine therapy combined with the groundbreaking use of CDK4/6 inhibitors in the metastatic first-line setting. Approximately 50%–60% of these patients have “bone-only” metastatic disease. In...
Main Authors: | Ilona Tornyi, Peter Árkosy, Ildikó Horváth, Andrea Furka |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-10-01
|
Series: | Pathology and Oncology Research |
Subjects: | |
Online Access: | https://www.por-journal.com/articles/10.3389/pore.2023.1611369/full |
Similar Items
-
Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases
by: Marcin Kubeczko, et al.
Published: (2023-03-01) -
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01) -
Application of nanomedicine in radiotherapy sensitization
by: Xiaoyu Song, et al.
Published: (2023-02-01) -
Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
by: Ioana-Miruna Stanciu, et al.
Published: (2023-04-01) -
Radiotherapy in bone sarcoma: the quest for better treatment option
by: Marie-Anaïs Locquet, et al.
Published: (2023-08-01)